Last reviewed · How we verify
Progevera
At a glance
| Generic name | Progevera |
|---|---|
| Sponsor | Fundació Privada Eugin |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA) (NA)
- A Study Run At Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also Be Used to Assess Changes of Severity of HMB in Women with HMB Who Are Treated During 12 Months with a Chronic Hormonal Treatment
- Comparison of Two PPOS Models for Pituitary Suppression (NA)
- Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Progevera CI brief — competitive landscape report
- Progevera updates RSS · CI watch RSS
- Fundació Privada Eugin portfolio CI